GLP-1 cardiovascular protection appears similar across age groups

Published October 27, 2026 · Systematic synthesis of eight randomized outcome trials · Clinically relevant
Primary source: Age-stratified GLP-1RA meta-analysis, PMID 42946897

Older adults are often underrepresented in trials, and relative treatment effects might differ with age. This analysis pooled age-stratified major adverse cardiovascular event data from eight placebo-controlled GLP-1 receptor agonist trials involving 71,926 participants with diabetes or overweight/obesity.

Pooled hazard ratios for major adverse cardiovascular events were 0.81 (95% CI 0.69–0.94) for participants younger than 65 and 0.84 (0.79–0.90) for those 65 and older. The between-age-group ratio of hazard ratios was 1.03 (0.85–1.25): no clear evidence of age modification. But that interval does not prove identical effects. Only four trials supplied the finer ≥75-year subgroup, which remained relatively small. Absolute event reductions were not consistently reported in the abstract and are not inferred here.

Strength and limitations. These are randomized cardiovascular endpoint trials synthesized at the subgroup level, but heterogeneity and differences in drugs, risk, and age distributions remain. It is not an age-specific randomized assignment to different drugs, and a null interaction test does not demonstrate equivalence.

Clinical practice: Age alone need not exclude indicated GLP-1 treatment, but individual frailty, nutrition, muscle and bone health, contraindications, and costs still matter.